NAVB vs. MYMD, VRAX, BMRA, GOVX, PHAS, NEXI, BACK, MDXH, SNES, and LUCY
Should you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include MyMD Pharmaceuticals (MYMD), Virax Biolabs Group (VRAX), Biomerica (BMRA), GeoVax Labs (GOVX), PhaseBio Pharmaceuticals (PHAS), NexImmune (NEXI), IMAC (BACK), MDxHealth (MDXH), SenesTech (SNES), and Innovative Eyewear (LUCY). These companies are all part of the "medical" sector.
Navidea Biopharmaceuticals (NYSE:NAVB) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.
In the previous week, MyMD Pharmaceuticals had 2 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 2 mentions for MyMD Pharmaceuticals and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 beat MyMD Pharmaceuticals' score of -0.50 indicating that Navidea Biopharmaceuticals is being referred to more favorably in the media.
0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of MyMD Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
MyMD Pharmaceuticals has lower revenue, but higher earnings than Navidea Biopharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than MyMD Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Navidea Biopharmaceuticals has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.29, suggesting that its stock price is 129% more volatile than the S&P 500.
Navidea Biopharmaceuticals and MyMD Pharmaceuticals both received 0 outperform votes by MarketBeat users.
Navidea Biopharmaceuticals' return on equity of 0.00% beat MyMD Pharmaceuticals' return on equity.
Summary
MyMD Pharmaceuticals beats Navidea Biopharmaceuticals on 6 of the 11 factors compared between the two stocks.
Get Navidea Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Navidea Biopharmaceuticals Competitors List
Related Companies and Tools
